Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference20 articles.
1. Cancer Survivorship, Atlanta (GA): Center for disease Control and Prevention (US), national Center for Chronic disease Prevention and health Promotion. http://www.cdc.gov/cancer/survivorship/pdf/survivorship_fs.pdf(Accessed 23 May 2018).
2. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised con- trolled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006
3. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2011
4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002
5. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin’s lymphoma patients in England;Leukemia Research;2023-04
2. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659);Oncotarget;2023-01-26
3. Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors;Annals of Hematology;2023-01-09
4. Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy;Advances in Radiation Oncology;2022-11
5. Risk and outcome of acute myeloid leukaemia among survivors of primary diffuse large B-cell lymphoma: a retrospective observational study based on SEER database;BMJ Open;2022-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3